The majority of women with epithelial ovarian cancer present the disease at a postmenopausal stage where circulating follicle stimulating hormone (FSH) and lutenizing hormone (LH) levels are elevated, indicating a causal relationship between chronically elevated gonadotropin levels and ovarian cancer development [5], [8]. The gene discussed is BRD2; the disease is ovarian carcinoma.